Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Comparison of Cardiovascular Cardiovascular Events Event Candesartan Amlodipine p Hazard Ratio P Value (n=2354) (n=2349) Cardesartan/Amlodipine Cardiovascular events 134 (5.7%) 134 (5.7%) 0.969 Sudden deaths 11 (0.5%) 15 (0.6%) 0.434 Cerebrovascular events Cardiac events 61 43 (2.6%) (1.8%) 50 47 (2.1%) (2.0%) 0.282 0.680 Renal events 19 (0.8%) 27 (1.1%) 0.230 Vascular events 11 (0.5%) 7 (0.3%) 405 4.05 0.348 0.25 0.5 1 2 Favors Candesartan Favors Amlodipine 4
CASE CASE-J: CASE CASE-J: J: Candesartan Antihypertensive Survival Evaluation in Japan BP (mmHg) 180 160 140 120 100 80 60 162.5 163.2 91.6 91.8 143.5 141.4 82.0 80.7 141.6 139.7 80.7 79.7 Candesartan Amlodipine 139.7 138.2 137.7 136.7 79.8 78.5 78.8 78.2 Baseline 6 Months 12 Months 18 Months 24 Months 2364 2246 2157 2071 1970 2364 2250 2155 2076 1967
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr

Comparison of Candesartan vs Amlodipine Comparison of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?